China blueprints drug-safety improvements

Chinese officials rolled out a plan to improve drug standards and monitoring over the next 5 years, saying "[m]edicinal safety is in a high-risk stage." Among the goals are stepped-up monitoring of adverse events, a credit-rating system, post-marketing surveillance and severe punishments for counterfeiters and misbehaving drug executives. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.